Holen Sie sich die Stockscreener-App
52.14
4.16%
2.08
Handel nachbörslich:
52.55
0.41
+0.79%
Corcept Therapeutics Inc Aktie (CORT) Neueste Nachrichten
Here is Why Growth Investors Should Buy Corcept (CORT) Now - Yahoo Finance
Corcept (CORT) Upgraded to Strong Buy: Here's Why - Yahoo Finance
Corcept Therapeutics Incorporated (CORT) Soars to 52-Week High, Time to Cash Out? - Yahoo Finance Australia
Corcept Stock At New High; Will The Upcoming Regulatory And Clinical Trial Catalysts Take It Higher? - RTTNews
Roman Butler Fullerton & Co. Sells 10,466 Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) - MarketBeat
Creative Planning Acquires 841 Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) - Defense World
Corcept Therapeutics (NASDAQ:CORT) Reaches New 1-Year HighStill a Buy? - MarketBeat
Corcept Therapeutics stock soars to all-time high of $50.23 By Investing.com - Investing.com Australia
Corcept Therapeutics stock soars to all-time high of $50.23 - Investing.com
Wall Street Analysts Believe Corcept (CORT) Could Rally 56.66%: Here's is How to Trade - Yahoo Canada Finance
Recent Price Trend in Corcept (CORT) is Your Friend, Here's Why - Yahoo Canada Finance
What is HC Wainwright’s Forecast for CORT FY2024 Earnings? - Defense World
Research Analysts Issue Forecasts for CORT FY2024 Earnings - MarketBeat
What is HC Wainwright’s Estimate for CORT FY2026 Earnings? - Defense World
Corcept Trumps Q3 Earnings & Sales Estimates, Ups '24 Revenue View - MSN
Corcept Therapeutics (CORT) Stock Declines Amid Market Activity - GuruFocus.com
Earnings Estimates Moving Higher for Corcept (CORT): Time to Buy? - MSN
Corcept Therapeutics (NASDAQ:CORT) Stock Price Down 3.2%Here's What Happened - MarketBeat
FY2026 Earnings Estimate for CORT Issued By HC Wainwright - MarketBeat
Corcept Therapeutics Incorporated (NASDAQ:CORT) Q3 2024 Earnings Call Transcript - Insider Monkey
Corcept’s relacorilant GRADIENT trial misses primary endpoint - Yahoo Finance
Corcept Therapeutics Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
Earnings call: Corcept Therapeutics reports robust Q3 growth, raises guidance - Investing.com Canada
Corcept Therapeutics Inc (CORT) Q3 2024 Earnings Call Highlights: Record Revenue Growth and Strategic Expansion - GuruFocus.com
Corcept Therapeutics Inc (CORT) Q3 2024 Earnings: EPS of $0.41 B - GuruFocus.com
HC Wainwright Reiterates Buy Rating for Corcept Therapeutics (NASDAQ:CORT) - MarketBeat
Corcept Therapeutics (CORT) Tops Q3 Earnings and Revenue Estimates - MSN
Corcept: Q3 Earnings Snapshot - Milford Mirror
Corcept reports robust revenue growth in Q3 By Investing.com - Investing.com Canada
abrdn plc Purchases 142,310 Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) - MarketBeat
Corcept Therapeutics Announces Third Quarter Financial Results, Positive Results From Phase 3 GRADIENT Trial in Patients With Cushing’s Syndrome and Provides Corporate Update - StockTitan
Earnings Preview: Corcept Therapeutics - Benzinga
Boston Trust Walden Corp Sells 69,924 Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) - MarketBeat
Corcept Therapeutics (CORT) Set to Announce Earnings on Wednesday - MarketBeat
Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call - Yahoo Finance
Strength Seen in Corcept (CORT): Can Its 5.5% Jump Turn into More Strength? - MSN
Zacks.com featured highlights Idaho Strategic, Qifu, Sezzle, Corcept and FinWise - Yahoo Finance
Corcept stock stays a buy, with analyst eyeing validation of relacorilant’s cancer-fighting mechanism - Investing.com UK
Analysts Set Corcept Therapeutics Incorporated (NASDAQ:CORT) PT at $65.25 - Defense World
Corcept Therapeutics Incorporated (NASDAQ:CORT) Position Reduced by Exchange Traded Concepts LLC - Defense World
Exchange Traded Concepts LLC Decreases Stock Position in Corcept Therapeutics Incorporated (NASDAQ:CORT) - MarketBeat
Corcept Therapeutics Incorporated (NASDAQ:CORT) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
Corcept Therapeutics (CORT) Stock Jumps Over 5% Amid Solid Finan - GuruFocus.com
HC Wainwright Increases Corcept Therapeutics (NASDAQ:CORT) Price Target to $80.00 - MarketBeat
Corcept Therapeutics stock target raised, buy rating on Cushing's franchise growth - Investing.com Canada
Key Takeaways From Corcept Therapeutics Analyst Ratings - Benzinga
Corcept Therapeutics (NASDAQ:CORT) Sets New 12-Month HighHere's Why - MarketBeat
Wall Street Analysts See a 43.01% Upside in Corcept (CORT): Can the Stock Really Move This High? - Yahoo Finance
Corcept Therapeutics stock hits all-time high at $47.81 - Investing.com
Corcept Therapeutics stock hits all-time high at $47.81 By Investing.com - Investing.com UK
Corcept (CORT) Is a Great Choice for 'Trend' Investors, Here's Why - Yahoo Finance
Cetera Investment Advisers Boosts Position in Corcept Therapeutics Incorporated (NASDAQ:CORT) - Defense World
Creative Planning Purchases 1,794 Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) - Defense World
Here's Why Investors Should Consider Buying Corcept Stock Now - MSN
Truist upgrades Corcept Therapeutics Inc (CORT) rating to a Buy - Knox Daily
Corcept Therapeutics Inc (CORT) stock analysis: A simple moving average approach - US Post News
Financial Analysis: Corcept Therapeutics Inc (CORT)’s Ratios Unveil Key Insights - The Dwinnex
Implied Volatility Surging for Corcept Therapeutics (CORT) Stock Options - Yahoo Finance
2.02%
0.47%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):